Across TCGA pan-cancer cohorts, MAPK11 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MAPK11 data layer compared with 22 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MAPK11 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MAPK11 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LUAD, LSCC, and HNSC are the cancer types where MAPK11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	III,IV	0.292	0.867	.007	29	view →
LSCC	OS	Quartile	II,III,IV	0.453	0.830	.006	4	view →
HNSC	DFS	Quartile	All	0.825	0.438	.010	3	view →
GBM	OS	Tertile	All	0.405	0.604	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: MAPK11 tumor-vs-normal RNA expression · all MAPK11 data types